TY - JOUR
T1 - SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders
AU - Busca, Alessandro
AU - Cesaro, Simone
AU - Teofili, Luciana
AU - Delia, Mario
AU - Cattaneo, Chiara
AU - Criscuolo, Marianna
AU - Marchesi, Francesco
AU - Fracchiolla, Nicola Stefano
AU - Valentini, Caterina Giovanna
AU - Farina, Francesca
AU - Di Blasi, Roberta
AU - Prezioso, Lucia
AU - Spolzino, Angelica
AU - Candoni, Anna
AU - Del Principe, Maria Ilaria
AU - Verga, Luisa
AU - Nosari, Annamaria
AU - Aversa, Franco
AU - Pagano, Livio
PY - 2018
Y1 - 2018
N2 - Introduction: The rapid spread of severe infections mainly due to resistant pathogens, justifies the search for therapies aiming to restore immune functions severely compromised in patients with hematologic malignancies. Areas covered: The present review summarizes the current knowledge on the role of granulocyte transfusions and colony-stimulating factors as treatment strategy for hematologic patients with serious infectious complications. In addition, a survey among 21 hematologic centers, to evaluate the clinical practice for the use of G-CSF originator and biosimilars was performed. Expert commentary: Granulocyte transfusions with a target dose of at least 1.5-3 Ã 108cells/kg, may be considered as an approach to bridge the gap between marrow suppression and recovery of granulocytes. G-CSF shortens the period of neutropenia, the hospitalization, the use of antibiotics and the rate of febrile neutropenia (FN) in adult and pediatric patients with non-Hodgkin lymphoma, and in adults with acute myeloid leukemia where these advantages nevertheless, did not translate into a clinical benefit. G-CSF biosimilar showed equivalence or non-inferiority to filgrastim. There are no data supporting the use of GM-CSF, eltrombopag and erythropoietin for preventing or treating infectious complications in patients with hematologic disorders.
AB - Introduction: The rapid spread of severe infections mainly due to resistant pathogens, justifies the search for therapies aiming to restore immune functions severely compromised in patients with hematologic malignancies. Areas covered: The present review summarizes the current knowledge on the role of granulocyte transfusions and colony-stimulating factors as treatment strategy for hematologic patients with serious infectious complications. In addition, a survey among 21 hematologic centers, to evaluate the clinical practice for the use of G-CSF originator and biosimilars was performed. Expert commentary: Granulocyte transfusions with a target dose of at least 1.5-3 Ã 108cells/kg, may be considered as an approach to bridge the gap between marrow suppression and recovery of granulocytes. G-CSF shortens the period of neutropenia, the hospitalization, the use of antibiotics and the rate of febrile neutropenia (FN) in adult and pediatric patients with non-Hodgkin lymphoma, and in adults with acute myeloid leukemia where these advantages nevertheless, did not translate into a clinical benefit. G-CSF biosimilar showed equivalence or non-inferiority to filgrastim. There are no data supporting the use of GM-CSF, eltrombopag and erythropoietin for preventing or treating infectious complications in patients with hematologic disorders.
KW - Hematologic malignancies
KW - Hematology
KW - colony-stimulating factors
KW - granulocyte transfusions
KW - infectious complications
KW - invasive fungal infections
KW - Hematologic malignancies
KW - Hematology
KW - colony-stimulating factors
KW - granulocyte transfusions
KW - infectious complications
KW - invasive fungal infections
UR - http://hdl.handle.net/10807/111926
U2 - 10.1080/17474086.2018.1420472
DO - 10.1080/17474086.2018.1420472
M3 - Article
SN - 1747-4086
VL - 11
SP - 155
EP - 168
JO - Expert Review of Hematology
JF - Expert Review of Hematology
ER -